The Frequency of Reversible Parkinsonism and Cognitive Decline Associated with Valproate Treatment: A Study of 364 Patients with Different Types of Epilepsy

Purpose: We report the frequency of parkinsonism and cognitive decline (P/CD) in patients treated with valproate (VPA) after 1 year of treatment and at least 1 year of follow‐up. Methods: Three hundred sixty‐four patients with various epileptic syndromes and seizure types were treated with VPA mono‐...

Full description

Saved in:
Bibliographic Details
Published in:Epilepsia (Copenhagen) 2006-12, Vol.47 (12), p.2183-2185
Main Authors: RISTIC, Aleksandar J, VOJVODIC, Nikola, JANKOVIC, Slavko, SINDELIC, Aleksandra, SOKIC, Dragoslav
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Anticonvulsants - adverse effects
Anticonvulsants - therapeutic use
Anticonvulsants. Antiepileptics. Antiparkinson agents
Biological and medical sciences
Cognition Disorders - chemically induced
Cognition Disorders - epidemiology
Cognitive decline
Drug Administration Schedule
Drug Therapy, Combination
Drug toxicity and drugs side effects treatment
Epilepsy
Epilepsy - classification
Epilepsy - diagnosis
Epilepsy - drug therapy
Female
Follow-Up Studies
Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy
Humans
Longitudinal Studies
Male
Medical sciences
Middle Aged
Nervous system (semeiology, syndromes)
Neurology
Neuropharmacology
Parkinson Disease, Secondary - chemically induced
Parkinson Disease, Secondary - epidemiology
Parkinsonism
Pharmacology. Drug treatments
Prevalence
Severity of Illness Index
Toxicity: digestive system
Treatment Outcome
Valproate
Valproic Acid - adverse effects
Valproic Acid - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: We report the frequency of parkinsonism and cognitive decline (P/CD) in patients treated with valproate (VPA) after 1 year of treatment and at least 1 year of follow‐up. Methods: Three hundred sixty‐four patients with various epileptic syndromes and seizure types were treated with VPA mono‐ or polytherapy for more than 1 year. Results: We found five cases of P/CD (1.37%; 95% CI, 0.18–2.56%). Among 140 patients with different adverse effects (AEs) of VPA, P/CD were among the rarest in frequency but significant in terms of drug discontinuation (five of 17). Conclusions: Early identification of this type of AE and discontinuation of the drug led to complete recovery in affected patients.
ISSN:0013-9580
1528-1167
DOI:10.1111/j.1528-1167.2006.00711.x